M. Morán

Dolutegravir plus rilpivirine: benefits beyond viral suppression

J. Troya, C. Galera, M. Montero, 2022, Medicine.

Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

J. Troya, L. Rodríguez, J. Iribarren, 2023, Viruses.

Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

D. Podzamczer, J. Mallolas, J. Losa, 2021, Trials.

Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus.

G. Ruiz-Irastorza, I. Cabezas-Rodríguez, A. Ugarte, 2014, Rheumatology.

An NMR-Based Model to Investigate the Metabolic Phenoreversion of COVID-19 Patients throughout a Longitudinal Study

Shelly C. Lu, R. Gil-Redondo, M. Spraul, 2022, Metabolites.

Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

D. Podzamczer, J. Mallolas, J. Losa, 2021, Trials.

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

J. Troya, J. Iribarren, I. de los Santos, 2023, Viruses.